Login
← Go Back
Divi's Laboratories
DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com
Stock Price vs Company Growth
1d
4.8%
1w
9.7%
1m
19.6%
3m
12.5%
6m
18.0%
1y
25.4%
5y
19.4%
10y
20.5%
all
21.8%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 4,025 4.8%
3,350
4,040
Company Overview
Sales
7,493 Cr
Growth: -8.3%
Profit after Tax
1,383 Cr
Growth: 3.9%
Large Cap
1,06,860 Cr
P/E: 77.2x
Industry P/E: 35.5x
Fundamentals
Sales (Cr) ₹ 7,493
Growth -8.3%
EBITDA 26.2%
P/S 14.3x
Dividend 0.8%
P/E 77.2x
Book Value ₹ 521
PEG Ratio -9.3x
ROE 10.4%
P/B 7.7x
Shareholding Pattern
Institutions
Sbi Mutual Fund
4.49 %
Qualified Institutional Buyer
3.57 %
Axis Mutual Fund Trustee Ltd
3.37 %
Government Pension Fund Global
1.29 %
Life Insurance Corporation Of India
1.15 %
Promoters
Nilima Prasad Divi
20.34 %
Divi Satchandra Kiran
20.34 %
Divi Swarna Latha
5.27 %
Divi'S Biotech Private Limited
3.01 %
Murali Krishna Prasad Divi
2.85 %
Others
Increase    Decrease    No change
Company Profile Detailed
The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.
Belongs to (32 Indices) view more
Investors (128)
valiant....
baron.em...
iepf
Followers (41)
deepak
jayapras...
nitin2